Cardace-AM

Quick links to important sections

Cardace-AM

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardace-AM

Property Description
Active Ingredients Ramipril, Amlodipine
Form Oral tablet (fixed-dose combination)
Pharmacological Class Antihypertensive Agents
General Purpose Long-term blood pressure regulation
Origin Synthetic pharmaceutical compounds

Cardace-AM is a synthetic, prescription-only medication classified broadly as an Antihypertensive Agent, delivered as an oral tablet for long-term blood pressure regulation. As a well-known fixed-dose combination product manufactured by Sanofi, it is distinct from generic single-component alternatives. This combination is specifically used to manage high blood pressure.

What Type of Medicine Is Cardace-AM?

Cardace-AM is a fixed-dose combination product that merges two distinct pharmacological actions into a single oral tablet. This formulation is often utilized in adult patients to simplify the complex regimen required for managing essential hypertension. The combination offers a comprehensive therapeutic strategy based on the benefits of combining these agents.

Composition: Ramipril, Amlodipine, and Their Combined Action

The formulation contains two active ingredients: Ramipril and Amlodipine. Ramipril is an Angiotensin-Converting Enzyme (ACE) Inhibitor, and Amlodipine is a dihydropyridine derivative Calcium Channel Blocker (CCB). This specific co-formulation is designed to create a therapeutic synergy, where the two agents address different pathways of blood pressure elevation, resulting in a more effective and comprehensive reduction in vascular resistance than either compound typically achieves alone.

General Purpose of This Dual-Action Combination

The general purpose of Cardace-AM is to utilize its dual mechanism to achieve consistent and comprehensive blood pressure regulation throughout the day. By simultaneously addressing two distinct targets for lowering pressure, the medication reduces the physical workload on the heart. This action provides the general benefit of sustaining a healthier circulatory environment, which is fundamental to the long-term goal of cardiovascular risk reduction.

Regulatory References

  1. Amlodipine and Benazepril Combination Drug Information (Classically analogous ACE/CCB)

What side effects are possible with Cardace-AM?

Possible Side Effects and Safety Information

Cardace-AM combines the effects of an Angiotensin-Converting Enzyme (ACE) inhibitor (ramipril) and a calcium channel blocker (amlodipine), leading to a safety profile that includes reactions from both drug classes.

Common Adverse Reactions

The most frequently reported side effects include headache, dizziness, cough (non-productive), and edema (swelling, particularly of the ankles or feet). Other common reactions involve the gastrointestinal system (e.g., nausea, abdominal pain, diarrhea) and general symptoms like fatigue, palpitations, and muscle cramps.

System/Organ Class Common Adverse Reactions (Approximate Incidence 1%–10%)
Nervous System Headache, Dizziness
Cardiovascular Edema, Palpitations, Flushing, Hypotension (low blood pressure)
Respiratory Dry, Non-Productive Cough
Gastrointestinal Nausea, Abdominal discomfort, Diarrhea
General Fatigue, Chest pain, Muscle cramps

Serious and Clinically Significant Safety Information

Angioedema is a serious, potentially life-threatening reaction associated with ACE inhibitors, involving swelling of the face, lips, tongue, or throat, and requiring immediate medical attention. Severe hypotension (very low blood pressure) and hyperkalemia (increased potassium levels in the blood, which can be dangerous for the heart) are also known risks, often requiring careful monitoring, especially at the start of therapy. Acute myocardial infarction or stroke have been reported in association with excessive hypotension.

Contraindications and Warnings

Cardace-AM is contraindicated in patients with a history of angioedema related to prior ACE inhibitor use and in the second and third trimesters of pregnancy due to the risk of fetal injury or death. It is also contraindicated for use with sacubitril/valsartan and with aliskiren in patients with diabetes or moderate-to-severe renal impairment. Caution is required in patients with liver disease, kidney impairment, and severe heart conditions like aortic stenosis. Patients should be advised that the medication may cause dizziness or tiredness, affecting the ability to drive or operate machinery.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cardace-AM (Ramipril/Amlodipine) is primarily characterized by profound cardiovascular effects, as documented in official regulatory labeling. The recognized clinical manifestations of overexposure include marked hypotension (severe low blood pressure) and excessive peripheral vasodilatation (widespread vessel widening). Clinical signs also list bradycardia (slow heart rate) and potentially reflex tachycardia.

Serious Outcomes and Emergency Action

Regulatory sources classify massive overdose as having the potential for life-threatening consequences, which may include shock, renal failure, and severe electrolyte disturbances. Due to these risks, patients must seek immediate medical attention by calling emergency services for any suspected overexposure. Emergency management requires immediate initiation of active cardiac and respiratory monitoring and frequent blood pressure measurements until stability is achieved.

Supportive Measures and Constraints

Management focuses on cardiovascular support, utilizing measures such as volume and salt substitution (intravenous fluids) and the administration of vasopressors if hypotension is refractory. Regulatory documents confirm that no specific antidote is known for this combination, and hemodialysis is not likely to be of benefit due to the high protein binding of the amlodipine component. No unique population-specific overdose considerations are explicitly documented in the official labeling.

Therapeutic Uses of Cardace-AM

What Cardace-AM Treats: Main Uses and Benefits

The primary therapeutic area for Cardace-AM is applied across domains where additional symptomatic support is needed for high blood pressure, and it generally supports cardiovascular health. The combination is commonly used to help with the management of the primary condition of hypertension in adults.

This medication is primarily indicated for the treatment of essential hypertension (conditions marked by increased physiological stress), and is considered relevant when supportive symptom management is appropriate, especially when symptoms related to systemic imbalance are not adequately managed by a single agent alone. The treatment generally supports blood pressure reduction, which helps maintain a sense of stability when symptoms are more noticeable. The key therapeutic domains include support for conditions where functional stability becomes affected by hypertension, and easing symptoms linked to vascular stress, such as symptomatic chest discomfort (angina).

“The goal of this therapy is to assist with maintaining functional stability and supports the patient during difficult episodes by easing distress related to systemic imbalance.”

Quick Fact: Relief for Systemic Strain

This combination treatment provides support that helps ease the overall symptom burden related to long-term physiological strain, contributing to improved comfort during periods of heightened symptoms. For high-risk patient groups, such as those with Type 2 diabetes, the medication supports general well-being during symptomatic phases and may assist with maintaining functional stability.

Regulatory References

  1. Therapeutic indications for Ramipril/Amlodipine

Eligibility and Restrictions for Use

Who Can and Cannot Use Cardace-AM?

Eligibility for Cardace-AM (Ramipril/Amlodipine) is strictly defined by official regulatory criteria, focusing on age, patient history, and coexisting medical conditions. The medicine is primarily indicated for adults (18 years and older) whose blood pressure is already controlled by the individual components taken concurrently as separate tablets (substitution therapy).


Absolute Restrictions (Contraindications)

Cardace-AM must not be used by patients with the following conditions, as stated in the product labeling:

  • A history of angioedema (swelling) related to previous ACE inhibitor or ARB therapy.
  • Pregnancy during the second and third trimesters. Use must be discontinued immediately if pregnancy is detected.
  • Severe hypotension, shock, or obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis).
  • Concomitant use with aliskiren in patients with diabetes mellitus or moderate-to-severe renal impairment.

Populations Requiring Caution or Exclusion

  • Children and Adolescents: Use is not recommended in those under 18 years of age, as safety and efficacy for the fixed-dose combination have not been established.
  • Lactation: Use is not recommended in breastfeeding women.
  • Organ Impairment: Caution is required, and use is often not recommended, in patients with severe hepatic impairment or certain forms of severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other medicinal products and substances as officially documented in government regulatory labeling.

Contraindicated Combinations and Restrictions

Co-administration with Aliskiren is contraindicated in patients diagnosed with diabetes mellitus or those with moderate-to-severe renal impairment (Glomerular Filtration Rate GFR < 60 mL/min/1.73m^2). The official profile also restricts the concurrent use of Angiotensin Receptor Blockers (ARBs) in patients with diabetic nephropathy.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions involving CYP3A4 inhibitors (e.g., diltiazem) are documented to increase Amlodipine plasma concentration. Conversely, CYP3A4 inducers (e.g., rifampicin, St. John's Wort) may reduce Amlodipine exposure. The Ramipril component is officially stated to reduce the renal clearance of Lithium, increasing the risk of toxicity. Co-administration with Potassium-sparing diuretics or Potassium supplements increases the risk of Hyperkalemia due to an additive effect.

Exposure Modification and Consumables

Regulatory documents mandate a restriction on the dosage of Simvastatin when co-administered due to increased systemic exposure. Grapefruit or Grapefruit juice is documented to increase Amlodipine exposure. Furthermore, alcohol consumption is noted to enhance the hypotensive effect.

Mechanism of Action

Cardace-AM combines two pharmacologic agents: ramipril and amlodipine.

Ramipril functions as a pro-drug, which is hydrolyzed to its active metabolite, ramiprilat, primarily in the liver. Ramiprilat is a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), also known as kininase II. ACE inhibition prevents the conversion of the inactive decapeptide angiotensin I to the potent vasoconstrictor octapeptide angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS).

Reduced formation of angiotensin II lowers systemic levels of this peptide, decreasing its activation of the AT1 receptor on vascular smooth muscle cells. This mitigates AT1-mediated intracellular signaling, leading to decreased myocyte contraction and vasoconstriction. Ramiprilat also reduces the breakdown of bradykinin, a potent vasodilator, by inhibiting kininase II activity. The resultant accumulation of bradykinin further promotes vasodilation.

Amlodipine is a dihydropyridine calcium channel blocker. It functions as a selective antagonist, binding to and inhibiting the transmembrane influx of calcium ions through L-type voltage-dependent calcium channels in vascular smooth muscle cells. This inhibition reduces the intracellular calcium necessary for the actin-myosin cross-bridge formation required for cellular contraction. The resulting direct relaxation of vascular smooth muscle decreases peripheral vascular resistance. The combined mechanisms of ramipril and amlodipine lead to a comprehensive modulation of peripheral resistance and systemic circulatory dynamics.

Dosage and Administration Information

The Ramipril/Amlodipine fixed-dose combination is administered via the oral route as a hard capsule, strictly intended for long-term blood pressure regulation. Its use follows a highly structured protocol.


Official Usage Protocol

This medication is generally not suitable for initiating treatment and is instead indicated as substitution therapy. This means it is designated for adult patients who have already achieved adequate blood pressure control by taking the individual components, ramipril and amlodipine, concurrently at the same established dose.

The medicine is taken once daily, and adherence to a consistent time of day is necessary to maintain stable blood concentration levels. The hard capsule must be swallowed whole and should not be chewed or crushed. It may be taken with or without food.


Dose Adjustment and Special Populations

Dosing recommendations may vary by region; however, the maximum strength approved for daily use is typically the 10 mg/10 mg combination. If a change in the established dose is required, the protocol requires that the individual components must be titrated separately before considering a switch to a different fixed-dose strength.

Specific constraints apply to certain populations. For patients with hepatic impairment, the dose of the Ramipril component is restricted, making strengths above 2.5 mg of Ramipril unsuitable. The combination is not recommended for use in children under 18 or in very old and frail patients. Additionally, consumption of grapefruit juice is advised against during the course of administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardace-AM

Evidence for Use in Essential Hypertension

The clinical evaluation for the use of Cardace-AM in high blood pressure (essential hypertension) was studied for both its short-term and intermediate-term effects. Researchers employed several types of trials, including Randomized Controlled Trials (RCTs), which compared the fixed-dose combination directly against taking only one of the components (monotherapy). The populations studied were typically adult and elderly individuals with high blood pressure, including those who were previously evaluated while taking single-agent therapy.

The primary metrics assessed included changes in Systolic and Diastolic Blood Pressure (BP), monitored via in-clinic measurements and 24-hour monitoring. Trials also tracked the rate of patients whose BP measurements fell within predefined target ranges during the research. The main research examined blood pressure measurements as surrogate endpoints; findings regarding long-term cardiovascular events are derived from trials of the individual components.


Evidence in Co-Existing Conditions (Type 2 Diabetes Mellitus)

Research was studied for specific patient subgroups who have co-existing conditions, notably adult patients with essential hypertension and a diagnosis of Type 2 Diabetes Mellitus. For this group, the evidence is largely derived from Subgroup Analyses of larger prospective studies and open-label Observational Clinical Studies. Studies focused on outcomes monitoring physiological strain or stress, including the achievement of specialized blood pressure goals and markers related to renal health (kidney function), such as estimated Glomerular Filtration Rate (eGFR).


What Remains Understudied and Uncertain

Long-term effects are not fully established through specific combination trials, as the follow-up durations were limited in core randomized trials. This means there is limited information for long-term outcomes specific to the fixed-dose combination. The research focus has been on short-to-intermediate blood pressure change, and evidence for the combination's impact on hard outcomes (major cardiovascular events) remains limited. Additionally, evidence for certain subgroups remains insufficient, and findings were mixed or inconsistent across all specific patient groups studied for.

Frequently Asked Questions (FAQ)

Common questions about Cardace-AM (FAQ)


Q: How quickly does Cardace-AM start working to lower blood pressure?

According to official product information, the blood pressure-lowering effect from the amlodipine component can begin within 4 to 8 hours after taking a single dose. However, achieving the full, intended therapeutic benefit of the medicine may require several weeks of consistent use.


Q: Does Cardace-AM affect the liver or kidney function?

Regulatory documents indicate that both the liver and kidneys play a role in how your body handles the medication. The ramipril component is activated in the liver, and the medicine is affected by severe liver or kidney problems. Regulatory documents indicate that monitoring of kidney health and related markers is often necessary, especially for patients with pre-existing conditions.


Q: Is it necessary to have blood tests done while taking Cardace-AM?

Official guidance indicates that laboratory monitoring is important while taking this medicine. Levels of potassium and markers related to kidney health (renal function) require monitoring, particularly when starting therapy or in patients taking other related medications.


Q: What happens if I take an extra dose of Cardace-AM by mistake?

Taking more than the prescribed dose can lead to an excessive lowering of blood pressure, known as severe hypotension, and related symptoms like dizziness and heart rate changes. Official information notes that emergency medical treatment may be necessary in case of a suspected overdose.


Q: Is Cardace-AM safe to take during pregnancy or while breastfeeding?

Official product information strictly contraindicates the use of this medicine during the second and third trimesters of pregnancy due to the risk of fetal injury or death. For the first trimester and while breastfeeding, its use requires review by a healthcare provider.


Q: Does Cardace-AM affect blood sugar levels?

The ramipril component is noted in official sources to potentially cause a lowering of blood sugar levels. In studies, ramipril is associated with a potential lowering of blood sugar. Official information notes that blood sugar monitoring is often necessary for patients with diabetes when treatment is started.


Q: Can patients with diabetes safely use Cardace-AM?

Official documents describe the use of this medicine for patients with hypertension who also have diabetes. However, its use is contraindicated if the patient is also taking Aliskiren or certain Angiotensin Receptor Blockers (ARBs), particularly when diagnosed with kidney damage related to diabetes (diabetic nephropathy).


Q: What is the typical time frame to see the maximum effect of Cardace-AM?

While an initial reduction in blood pressure occurs quickly, the maximum therapeutic benefit of the combined medication is achieved over a longer period. Official information suggests that it often takes several weeks for the dose to be fully established and for the steady, peak effect to be observed.


Q: Can Cardace-AM be split in half if the pill is scored?

Official documentation for the hard capsule formulation states that the medicine must be swallowed whole and should not be chewed or crushed. There are no general regulatory instructions allowing for the splitting of this medication.


Q: What happens if I forget to take my dose of Cardace-AM?

If a dose is forgotten, official patient information describes that it may be taken as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. Taking two doses to make up for a missed dose is not advised in official instructions.


Q: Does Cardace-AM cause weight gain or loss?

Significant weight gain or loss is not listed as a common side effect in official documents. Changes in weight have been reported as uncommon or rare reactions associated with the individual components of the medicine.


Q: Does Cardace-AM interact with pain relievers like ibuprofen?

Regulatory documents indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect of the ramipril component. This combination can also increase the risk of deterioration of kidney function.


Q: Is Cardace-AM safe to take long-term (e.g., for many years)?

The drug is prescribed for the long-term management of high blood pressure, which is a fundamental part of cardiovascular risk reduction. While the core research on the fixed-dose combination has had limited follow-up duration, studies on the individual components support their use over many years for this purpose.


Q: Can Cardace-AM be stopped suddenly, or does the dose need to be reduced slowly?

Official guidance for similar blood pressure medicines advises against stopping the medication suddenly without supervision. Abrupt cessation may lead to a quick increase in blood pressure. Any changes to the regimen, including stopping, are typically described as requiring a gradual dose reduction and supervision.


Q: What is the difference between Cardace-AM and other 'pril' or 'pine' medicines?

Cardace-AM is classified as a fixed-dose combination product, meaning it contains two different types of blood pressure medicine in a single pill. It combines Ramipril (a 'pril' medicine or ACE inhibitor) and Amlodipine (a 'pine' medicine or calcium channel blocker) to provide dual action.


Q: Does taking Cardace-AM make your heart rate slower?

A slow heart rate, known medically as bradycardia, is not a common side effect. However, official side effect lists for the individual components do note that irregular or slow heartbeats have been reported as uncommon or rare adverse reactions.


Q: Does Cardace-AM make you feel tired or fatigued?

Yes, fatigue and general tiredness are listed as common adverse reactions (occurring in 1% to 10% of patients) in official product information. This effect is a known possibility, which is why official warnings mention that the medicine may cause dizziness or tiredness.


Q: Can Cardace-AM be taken in the evening instead of the morning?

Official documentation states that the medication should be taken once daily at a consistent time of day. As long as consistency is maintained, regulatory sources do not specify whether the dose must be taken in the morning or the evening.


Q: What are the signs of a serious allergic reaction to Cardace-AM?

A severe allergic reaction can include the sudden, potentially life-threatening swelling of the face, lips, tongue, or throat, known as angioedema. Other signs may involve hives, severe itching, and difficulty breathing or swallowing. These symptoms are often described as requiring immediate medical attention.


Q: Is it normal for my skin to feel tingly or numb while taking Cardace-AM?

Sensations of tingling, pins and needles, or numbness (medically termed paresthesia) are not common side effects. However, official side effect lists for the components do note these feelings as uncommon adverse reactions.


Q: Can Cardace-AM be used to prevent a heart attack or stroke?

The drug is officially indicated for essential hypertension, which is a fundamental part of cardiovascular risk reduction. While research on the individual components supports reducing the risk of hard outcomes like heart attack or stroke, the evidence specifically for the combination's direct impact on these events is noted as limited.


Q: Are there different dosages of Cardace-AM available?

Yes, the fixed-dose combination is available in a variety of strengths, such as the 2.5 mg/5 mg, 5 mg/5 mg, 10 mg/5 mg, 5 mg/10 mg, and 10 mg/10 mg combinations of ramipril and amlodipine.


Q: Why might a doctor switch me from another blood pressure medicine to Cardace-AM?

The medicine is officially indicated as a substitution therapy for adult patients. This means it is typically prescribed to people whose blood pressure is already well-controlled by taking the individual components, ramipril and amlodipine, as separate tablets at the same dose.


Q: Does Cardace-AM interact with common cold or flu medications?

Regulatory documents include a warning against the concurrent use of this medicine with certain agents like ephedrine, noradrenaline, or adrenaline. These substances, which can increase blood pressure, are sometimes found in over-the-counter cold and flu preparations.


Q: Can I exercise normally while taking Cardace-AM?

Official safety information notes that the medicine may cause dizziness or tiredness, which can potentially affect your ability to perform physical activities. When taking blood pressure-lowering medicine, maintaining good hydration during exercise is generally noted as important to avoid hypotension.


Q: Do you need to take Cardace-AM with food or on an empty stomach?

The official product documentation states that the hard capsule can be taken with or without food. This provides flexibility in when you can take your daily dose.


Q: Can Cardace-AM affect my sleep pattern?

Official side effect lists note that insomnia, or difficulty sleeping, is an uncommon adverse reaction associated with the individual components of the medicine.


Q: What is the storage temperature requirement for Cardace-AM?

The medicine must be stored at a controlled room temperature, typically not exceeding 25 C to 30 C. It must be kept protected from excessive heat, moisture, and direct light to maintain its stability and effectiveness.


Q: Is Cardace-AM approved in my country?

The fixed-dose combination of ramipril and amlodipine has been granted marketing authorization based on approval documents from national and intergovernmental regulatory agencies like the FDA and EMA. This means it is available as a prescription medication in many countries worldwide.

How should Cardace-AM be stored and disposed of?

How to Store and Dispose of Cardace-AM

The storage and disposal of Cardace-AM (ramipril and amlodipine) must adhere strictly to official regulatory requirements to ensure product stability and safety.

Official Storage Conditions

Cardace-AM tablets must be stored at controlled room temperature, typically not exceeding 25 C to 30 C, and should be kept from freezing. The medication must be protected from excessive heat, moisture, and direct light.

For child safety, the product must be kept in its tightly closed container and stored in a location that is out of the sight and reach of children.

Disposal Instructions

Unused or expired Cardace-AM should be disposed of via a drug take-back program or as directed by local waste management authorities. The product must not be flushed down a toilet or poured into a drain, as this is restricted by environmental guidance. Always check the expiry date and discard expired medication safely.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardace-AM found in:

A-Z Index: